New program aims to close the gap in cancer trial diversity

NCT ID NCT06314672

Recruiting now Knowledge-focused Sponsor: Ohio State University Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a program called CUSP2CT, designed to increase the number of racial and ethnic minorities referred to and enrolled in cancer clinical trials. The program involves educational sessions, discussions, and patient navigation. Researchers will track changes in referral and enrollment rates over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this program could help more people from underrepresented groups join cancer clinical trials, making research results more widely applicable.
What could go wrong: This is an early-stage program testing whether the approach works. It may not lead to lasting changes in enrollment or be adopted by other clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID SYSTEM NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC AND LYMPHOID SYSTEM NEOPLASM MALIGNANT SOLID NEOPLASM

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.